Skip to main content
TipRanks
Go Ultimate75% OFF

Omega Diagnostics (CNSL) AI Stock Analysis

4 Followers
GB:CNSL

Omega Diagnostics

(LSE:CNSL)

Select Model
Rating:38Underperform
Price Target:GBX 1.50▲(3.45% Upside)
Action:downgraded
Date:11/11/26

The score is primarily constrained by weak financial performance, especially negative cash flow, declining revenue, and capital erosion. Technical trends are also negative, while the negative P/E and absent dividend yield provide no valuation support. The oversold RSI offers only limited offset.

Positive Factors
Low leverageThe company carries very little debt relative to equity, reducing financial risk and interest-related pressure. This conservative capital structure preserves flexibility to manage volatility, fund operations, or pursue development without the constraints associated with heavier borrowing.
Negative Factors
Revenue contractionThe recent return to revenue contraction after the 2024 rebound points to an unstable top-line trajectory. Sustained declines can weaken scale benefits, reduce the resources available for product development, and make it harder to absorb fixed operating costs across the business.

Omega Diagnostics (CNSL) vs. iShares MSCI United Kingdom ETF (EWC)

-40%-30%-20%-10%0%10%20%30%GB:CNSL-35.56%EWC+20.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 3.45M
Dividend Yield
―
Average Volume (3M)
461.84K
Price to Earnings (P/E)
-0.6
Beta (1Y)
0.96
Revenue Growth
-32.11%
EPS Growth
-559.65%
Country
UK
Employees
85
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Omega Diagnostics Business Overview & Revenue Model

Company Description

Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic...

How the Company Makes Money

Omega Diagnostics makes money primarily by selling diagnostic products and related components into healthcare, laboratory, and industrial supply chains. Key revenue streams typically include: (1) sales of finished IVD test kits (e.g., rapid tests and...

Omega Diagnostics Financial Statement Overview

Summary

Financial performance is weak overall: declining revenue, volatile and recently negative profitability, shrinking assets and equity, and persistently poor cash generation outweigh healthy gross margins and low leverage.

Income Statement

30Negative

Balance Sheet

38Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue5.47M6.97M8.33M9.77M7.55M8.54M
Gross Profit3.33M4.28M5.00M6.05M3.17M4.75M
EBITDA-1.25M-392.00K2.20M-73.00K-2.65M360.00K
Net Income-6.22M-5.83M1.57M-328.00K-3.86M-11.33M
Balance Sheet
Total Assets6.33M7.45M13.80M13.89M14.40M17.84M
Cash, Cash Equivalents and Short-Term Investments1.93M2.64M4.87M5.44M5.12M1.60M
Total Debt175.00K125.00K349.00K148.00K74.00K370.00K
Total Liabilities1.40M1.77M2.39M4.21M4.45M6.02M
Stockholders Equity4.93M5.68M11.41M9.68M9.95M11.82M
Cash Flow
Free Cash Flow-860.00K-1.39M-142.00K548.00K-3.31M-4.71M
Operating Cash Flow-774.00K-1.13M83.00K607.00K-3.15M-3.23M
Investing Cash Flow-683.00K-810.00K2.12M-2.51M5.18M-493.00K
Financing Cash Flow-172.00K-232.00K-251.00K-265.00K1.49M-502.00K

Omega Diagnostics Technical Analysis

Technical Analysis SentimentNegative
Last Price1.45

Price Trends

50DMA1.54Negative
100DMA1.67Negative
200DMA1.80Negative

Market Momentum

MACD-0.04Positive
RSI34.43Neutral
STOCH29.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CNSL, the sentiment is Negative. The current price of 1.45 is below the 20-day moving average (MA) of 1.54, below the 50-day MA of 1.54, and below the 200-day MA of 1.80, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 34.43 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CNSL.

Omega Diagnostics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:CNSL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:TSTLGB:TSTL80OutperformGBP 188.69M23.5323.05%3.62%10.02%19.83%
GB:AMSGB:AMS71OutperformGBP 617.83M166.761.44%1.65%6.05%-60.00%
GB:EKFGB:EKF64NeutralGBP 102.71M41.383.58%―2.26%-57.04%
GB:IXIGB:IXI55NeutralGBP 27.92M-6.50-16.18%―13.04%15.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:ABDXGB:ABDX46NeutralGBP 21.48M-15.45-34.31%―30.42%43.16%
GB:CNSLGB:CNSL38UnderperformGBP 3.45M-0.55-117.38%―-32.11%-559.65%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%GB:CNSLGB:AMSGB:EKFGB:IXIGB:TSTLGB:ABDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:CNSL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:CNSLOmega Diagnostics1.45-0.80-35.56%
GB:AMSAdvanced Medical Solutions283.5075.9236.58%
GB:EKFEKF Diagnostics Holdings24.00-0.90-3.61%
GB:IXIIXICO plc12.751.7515.91%
GB:TSTLTristel plc392.5041.3611.78%
GB:ABDXAbingdon Health PLC8.501.0013.33%

Omega Diagnostics Corporate Events

Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings

Cambridge Nutritional Sciences Reschedules AGM and Publishes 2026 Annual Report

Neutral
Sep 11, 2026

Cambridge Nutritional Sciences plc has rescheduled and finalised the notice of its Annual General Meeting for the financial year ended 31 March 2026. The AGM will now take place on 28 October 2026 at 2:00 p.m. at E-space North in Ely, ensuring compli...

Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings

Cambridge Nutritional Sciences Publishes Annual Report and Sets September AGM

Neutral
Sep 8, 2026

Cambridge Nutritional Sciences plc has published its Notice of Annual General Meeting and Annual Report and Accounts for the year ended 31 March 2026 on its corporate website. The documents provide shareholders and market participants with updated fi...

Business Operations and StrategyFinancial Disclosures

Cambridge Nutritional Sciences Cuts Costs and Refocuses Growth Amid Profit Slump

Negative
Sep 8, 2026

Cambridge Nutritional Sciences reported a decline in annual revenues to £7.0 million and a swing to a pre-tax loss of £4.4 million, hurt by delayed customer spending and a £3 million goodwill impairment, even as gross margins improved and cash reserv...

Business Operations and StrategyFinancial Disclosures

Cambridge Nutritional Sciences Delays Full-Year Results, Confirms Guidance

Neutral
Aug 17, 2026

Cambridge Nutritional Sciences plc, a specialist medical diagnostics company listed on AIM, focuses on personalised and functional health and nutrition solutions. The group operates in the nutrition diagnostics segment, where demand is being driven b...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026